Catalyst Wire Dossier Catalyst Wire Dossier

Nyxthracis

obiltoxaximab · SFL Pharmaceuticals Deutschland GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nyxthracis, covering 2024-09-09 to 2024-09-09. Get the full timeline:

Most recent: EMA Withdrawn: Nyxthracis (previously Obiltoxaximab SFL) (nyxthracis) — SFL Pharmaceuticals Deutschland GmbH

See pricing